Strategies to improve diversity, equity, and inclusion in clinical trials
Open Access
Abstract
There is a growing need for diversity, equity, and inclusion (DEI) in cancer care, particularly with respect to equal access and accrual to clinical trials. This commentary describe steps taken to address disparities in the authors' own clinical practice and proposes actions at the patient, provider, community, and institution levels to improve DEI in clinical trials.Keywords
Funding Information
- Alliance for Clinical Trials in Oncology Foundation (UG1 CA189823)
- National Center for Advancing Translational Sciences (KL2TR001874)
- National Institutes of Health (P30CA016058)
This publication has 26 references indexed in Scilit:
- Trajectory of Material Hardship and Income Poverty in Families of Children Undergoing Chemotherapy: A Prospective Cohort StudyPediatric Blood & Cancer, 2015
- Census categories for mixed race and mixed ethnicity: impacts on data collection and analysis in the US, UK and NZPublic Health, 2015
- The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research.2014
- Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?Cancer, 2013
- Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic reviewCancer, 2007
- Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based DisparitiesAnnals of Surgical Oncology, 2007
- Participation in Cancer Clinical TrialsJAMA, 2004
- Participation in cancer trials: recruitment of underserved populations.2003
- Assessing Capacity for Clinical Decisions and Research for Persons with Low English Proficiency: Ethical and Practical ChallengesHEC Forum, 2002
- Race/ethnicity and OMB Directive 15: implications for state public health practiceAmerican Journal of Public Health, 2000